Innovation And Flexibility To Overcome Challenges In A Metastatic Pancreatic Adenocarcinoma Study
Source: PRA Health Sciences
A randomized, double-blind, placebo-controlled, Phase II study evaluating the efficacy and safety of Study Drug A in combination with Study Drug B administered as first-line treatment to subjects with unresectable, locally advanced, or metastatic pancreatic adenocarcinoma.
PRA was awarded a global, full-service Phase II pancreatic cancer trial by a biotech client. The project was originally launched by a different company that PRA’s client had acquired. The first sites were opened in October, with first-patient-in occurring in January.
access the Case Study!
Log In
Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue.
X
Enter your credentials below to log in. Not yet a member of Clinical Leader? Subscribe today.
Subscribe to Clinical Leader
X
Subscribe to Clinical Leader
This website uses cookies to ensure you get the best experience on our website. Learn more